In a dramatic twist in the biotech sector, a subsidiary of National Resilience Holdco Inc. has filed for Chapter 11 bankruptcy protection, launching a high-stakes reorganization plan that involves shutting down a network of labs, offices, and manufacturing sites across the United States. Filed Tuesday in Delaware bankruptcy court, the move signals a stark reversal of fortune for a company once celebrated as a pandemic-era biomedical titan.
The entity at the center of the filing is Bedmar LLC, a once-ambitious offshoot tasked with powering the future of American biopharmaceutical production. But as independent bankruptcy manager Christopher S. Sontchi revealed, the company is now charting a course through financial turbulence by slashing its operational footprint.
Seven Sites, Zero Momentum
Bedmar’s reorganization strategy reads like a controlled demolition. The company is closing seven facilities located in California, Florida, and Massachusetts—each one labeled “underutilized” in court filings. These include sites in biotech hubs like Fremont and Bedford, which, according to Sontchi, never even opened their doors.
“The primary purpose of this Chapter 11 case is to wind down operations in an orderly manner and satisfy all allowed liabilities associated with the debtor’s idle assets,” Sontchi stated in a declaration that pulled no punches.
